Stereotaxis Reports 2025 Full Year Financial Results

Rhea-AI Summary

Stereotaxis (NYSE: STXS) reported 2025 results: revenue $32.4M (up 20% YoY) and Q4 revenue $8.6M (up 36% YoY). Recurring revenue was $22.2M (up 21%) and system revenue $10.2M (up 18%). Gross margin was ~53% for full year; cash was $13.4M with no debt.

Company highlighted US and EU approvals for GenesisX, MAGiC, and MAGiC Sweep and provided 2026 guidance targeting >$40M revenue and double-digit growth.

Positive

• Total revenue +20% year-over-year to $32.4M in 2025
• Q4 revenue +36% year-over-year to $8.6M
• Recurring revenue +21% to $22.2M in 2025
• System backlog $9.1M at start of 2026
• Cash balance $13.4M and no debt at December 31, 2025

Negative

• Full-year system gross margin only 21% due to low volumes
• Operating loss of $22.1M for 2025
• Adjusted operating loss $9.3M in 2025, still a material loss
• Manufacturing ramp challenges delayed commercial contribution from new products

Market Reaction – STXS

-4.83% $1.97

15m delay 1 alert

-4.83% Since News

$1.97 Last Price

$1.97 $2.11 Day Range

-$10M Valuation Impact

$193M Market Cap

1.3x Rel. Volume

Following this news, STXS has declined 4.83%, reflecting a moderate negative market reaction. The stock is currently trading at $1.97. This price movement has removed approximately $10M from the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Q4 2025 revenue: $8.6M Full-year 2025 revenue: $32.4M System backlog: $9.1M +5 more

8 metrics

Q4 2025 revenue $8.6M Fourth quarter 2025 total revenue vs $6.3M prior-year Q4

Full-year 2025 revenue $32.4M 2025 total revenue vs $26.9M in 2024 (20% growth)

System backlog $9.1M System backlog at start of 2026

Q4 2025 operating loss ($5.6M) GAAP operating loss for fourth quarter 2025

2025 adjusted operating loss ($9.3M) Full-year 2025 adjusted operating loss vs ($12.4M) prior year

Cash & equivalents $13.4M Cash and cash equivalents at December 31, 2025; no debt

Equity raised Q4 2025 $3.1M Raised via at-the-market offering at average price of $3.17

2026 revenue outlook >$40M Management expectation that 2026 annual revenue will surpass $40M

Market Reality Check

Price: $2.05 Vol: Volume 574,837 is 35% abo...

normal vol

$2.05 Last Close

Volume Volume 574,837 is 35% above the 20-day average of 427,014. normal

Technical Shares at $2.05 are trading below the 200-day MA of $2.50, well under the $3.59 52-week high.

Peers on Argus

STXS fell 6.39% while peers were mixed: OSUR up 10.76%, NYXH up 2.47%, MBOT up 0...

STXS fell 6.39% while peers were mixed: OSUR up 10.76%, NYXH up 2.47%, MBOT up 0.42%, STSS and INFU modestly down. Moves do not indicate a unified sector trend.

Previous Earnings Reports

5 past events · Latest: Nov 11 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 11	Q3 2025 earnings	Negative	-14.7%	Revenue decline versus prior year and continued operating and net losses.
Aug 07	Q2 2025 earnings	Positive	+14.2%	Strong 95% revenue growth and MAGiC Sweep FDA clearance with financing.
May 12	Q1 2025 earnings	Positive	+1.9%	Revenue growth led by recurring revenue and initial MAGiC commercialization.
Mar 03	2024 full-year earnings	Neutral	-5.8%	Flat annual revenue but multiple regulatory milestones and positive Q4 cash flow.
Nov 11	Q3 2024 earnings	Positive	+22.2%	18% revenue growth and CE Mark for GenesisX with new system orders.

Pattern Detected

Earnings releases often led to stock moves in the same direction as the underlying results, with four aligned reactions and one divergence, and strong growth quarters seeing notable upside.

Recent Company History

Over the last five earnings releases from Nov 2024 through Nov 2025, Stereotaxis reported recurring revenue growth and ongoing net losses while advancing GenesisX and MAGiC. Q3 and Q2 2025 showed mixed revenue trends but highlighted key regulatory clearances and commercial progress. Earlier, Q3 and full-year 2024 emphasized CE Mark achievements, initial GenesisX sales, and stable gross margins. Today’s full-year 2025 results extend this pattern of double-digit revenue growth alongside continued investment in the product ecosystem.

Historical Comparison

+3.5% avg move · Past earnings releases moved STXS an average of 3.54%, with most reactions aligning to growth or sof...

earnings

+3.5%

Average Historical Move earnings

Past earnings releases moved STXS an average of 3.54%, with most reactions aligning to growth or softness in results. This update continues the theme of revenue expansion alongside ongoing losses.

Earnings over 2024–2025 show recurring revenue growth, improving gross margins, and steady advancement of GenesisX, MAGiC, and digital solutions from regulatory milestones toward commercialization.

Market Pulse Summary

This announcement details Q4 and full-year 2025 results with revenue growing over 20%, improving adj...

Analysis

This announcement details Q4 and full-year 2025 results with revenue growing over 20%, improving adjusted operating loss, and no debt, alongside guidance that 2026 revenue should exceed $40M. It emphasizes regulatory approvals for GenesisX and MAGiC, manufacturing ramp plans, and digital surgery objectives. In context of prior earnings, investors may focus on recurring revenue growth, progress against the four stated 2026 milestones, cash levels of $13.4M, and the path toward sustained profitability.

Key Terms

pulsed field ablation, endovascular, electrophysiology, at-the-market offering, +4 more

8 terms

pulsed field ablation medical

"launch MAGiC with Pulsed Field Ablation in Europe."

Pulsed field ablation is a heart procedure that uses very short, high-voltage electrical pulses to selectively disrupt abnormal heart tissue that causes irregular rhythms, rather than heating or freezing it. For investors, it matters because this approach can shorten procedure times, reduce damage to nearby structures, and potentially lower complication rates compared with traditional thermal methods, which can affect device adoption, hospital costs, and market demand for treatment tools.

endovascular medical

"digital solution for the endovascular surgical suite, deliver over $3 million"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

electrophysiology medical

"only robotic technology in the attractive electrophysiology market."

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

at-the-market offering financial

"raised $3.1 million through its at-the-market offering at an average"

An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.

convertible preferred stock financial

"Cumulative dividend on convertible preferred stock"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

deferred revenue financial

"Deferred revenue | | 5,675 | | 6,804"

Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.

contingent consideration financial

"Current contingent consideration | | 4,894 | | 5,638"

Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.

operating lease liabilities financial

"Current portion of operating lease liabilities | | 642 |"

Long-term lease payments a company is legally committed to because it rents assets such as offices, factories, or equipment; under modern accounting rules these future rent obligations are recorded on the balance sheet as liabilities. Investors care because operating lease liabilities act like debt that drains future cash, affects measures of leverage and borrowing capacity, and can change profitability and valuation — think of them as a company’s large, ongoing rent payments that limit its financial flexibility.

AI-generated analysis. Not financial advice.

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025.

“The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I’m proud of what our team has accomplished and excited for the year ahead,” said David Fischel, Chairman and CEO.

“The highlight of the past year was achieving regulatory approvals in the United States and Europe for the GenesisX robot, MAGiC ablation catheter, and MAGiC Sweep high density mapping catheter. This core product portfolio serves as a foundation for significant commercial growth as the only robotic technology in the attractive electrophysiology market.”

“The commercial contribution from these new products was modest in 2025 as we worked through challenges in ramping manufacturing of MAGiC and GenesisX. Our primary goals this year are to demonstrate the commercial success of these products, ramp manufacturing substantially, and progress a robust pipeline of additional innovations. These are being advanced in a methodical and financially prudent fashion.”

Stereotaxis is focused on four key milestones this year:

1. GenesisX Robot – Establish at least five active GenesisX programs with global Electrophysiology key opinion leaders and demonstrate the accessibility of GenesisX with rapid installations in existing labs.
2. MAGiC & MAGiC Sweep Catheters – Ramp manufacturing of MAGiC to five hundred catheters a month by year end, transition Stereotaxis’ electrophysiology customers to MAGiC and MAGiC Sweep, and launch MAGiC with Pulsed Field Ablation in Europe.
3. Endovascular Robotics – Demonstrate a comprehensive strategy for technological leadership in robotics across interventional cardiology and neurointerventions.
4. Synchrony Digital Surgery Suite – Receive FDA approval for our digital solution for the endovascular surgical suite, deliver over $3 million in revenue, and complete development of the first AI features.

“This will be a busy and important year during which we establish manufacturing and commercial capabilities that support substantial revenue growth over a sustained multi-year period. In parallel, we continue to advance a robust pipeline of innovations in electrophysiology, endovascular robotics, and digital solutions that will increasingly reach development, regulatory and commercial milestones.”

2025 Fourth Quarter and Full Year Financial Results
Revenue for the fourth quarter of 2025 totaled $8.6 million, a 36% increase compared to $6.3 million in the prior year fourth quarter. System revenue for the quarter was $3.3 million and recurring revenue was $5.3 million, compared to $1.4 million and $4.9 million, respectively, in the prior year fourth quarter. System revenue in the fourth quarter of 2025 primarily reflects partial revenue recognition on two Genesis robots. Recurring revenue reflects contributions from MAGiC Sweep in the US and MAGiC in Europe. Revenue for the full year 2025 totaled $32.4 million, a 20% increase compared to $26.9 million in 2024. For the full year 2025, system revenue grew 18% to $10.2 million and recurring revenue grew 21% to $22.2 million. System backlog at the start of 2026 is $9.1 million.

Gross margin for the fourth quarter and full year 2025 were approximately 50% and 53% of revenue, respectively. Full year 2025 gross margins were 67% for recurring revenue and 21% for system revenue. Recurring gross margins were impacted by acquisition-related accounting that temporarily reduced disposable margin and by lower initial margins on newly launched devices. System gross margins remain impacted by fixed overhead allocated over low production levels. Operating expenses in the fourth quarter of $10.0 million include $3.0 million of non-cash charges for stock compensation expense, mark-to-market adjustment for acquisition related contingent earnout consideration, and amortization of acquired intangible assets. Excluding these non-cash charges, adjusted operating expenses in the quarter were $7.0 million. Adjusted operating expenses for the full year 2025 were $26.3 million, compared to $27.0 million in the prior year.

Operating loss and net loss in the fourth quarter of 2025 were ($5.6) million and ($5.5) million, respectively, compared to ($7.6) million and ($7.5) million in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash charges, were ($2.6) million and ($2.5) million, respectively, compared to ($3.8) million and ($3.6) million in the previous year. For the full year 2025, adjusted operating loss of ($9.3) million and adjusted net loss of ($8.8) million compared to an adjusted operating loss of ($12.4) million and an adjusted net loss of ($11.7) million in the prior year.

Cash Balance and Liquidity
At December 31, 2025, Stereotaxis had cash and cash equivalents of $13.4 million and no debt. During the fourth quarter, Stereotaxis raised $3.1 million through its at-the-market offering at an average stock price of $3.17.

Forward Looking Expectations
Stereotaxis anticipates double digit revenue growth for the full year 2026. Both system and recurring revenue are expected to increase over the course of the year in line with manufacturing ramps for GenesisX and MAGiC. Annual revenue is expected to surpass $40 million. Accomplishment of the four milestones for the year will support accelerated growth in future years.

Growing recurring revenue and stable operating expenses support an expectation for reduced cash use in 2026 compared to 2025. Stereotaxis expects positive cash flow from working capital following an investment of $5.6 million in working capital in 2025. The Company expects its balance sheet to allow it to advance its transformative product ecosystem to market, fund its commercialization, and achieve profitability.

Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, March 9, 2026, at 4:30 p.m. Eastern Time. To access the conference call, dial 800-715-9871 (US and Canada) or 646-307-1963 (International) and give the participant pass code 8365695. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions, including tariffs, on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly R. Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

Stereotaxis, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except share and per share amounts)	Three Months Ended December 31,								Year Ended December 31,
	2025				2024				2025				2024
Revenue:
Systems	$	3,360			$	1,389			$	10,223			$	8,632
Disposables, service and accessories		5,282				4,951				22,154				18,286
Total revenue		8,642				6,340				32,377				26,918
Cost of revenue:
Systems		2,485				1,120				8,028				6,880
Disposables, service and accessories		1,830				2,004				7,278				5,444
Total cost of revenue		4,315				3,124				15,306				12,324
Gross margin		4,327				3,216				17,071				14,594
Operating expenses:
Research and development		2,710				2,790				9,383				9,760
Sales and marketing		3,092				2,916				12,443				12,372
General and administrative		4,174				5,137				17,849				17,201
Other		-				-				(492	)			-
Total operating expenses		9,976				10,843				39,183				39,333
Operating loss		(5,649	)			(7,627	)			(22,112	)			(24,739	)
Other income		-				(2	)			2				-
Interest income, net		118				114				467				694
Net loss	$	(5,531	)		$	(7,515	)		$	(21,643	)		$	(24,045	)
Cumulative dividend on convertible preferred stock		(318	)			(324	)			(1,271	)			(1,308	)
Net loss attributable to common stockholders	$	(5,849	)		$	(7,839	)		$	(22,914	)		$	(25,353	)
Net loss per share attributed to common stockholders:
Basic	$	(0.06	)		$	(0.09	)		$	(0.25	)		$	(0.30	)
Diluted	$	(0.06	)		$	(0.09	)		$	(0.25	)		$	(0.30	)
Weighted average number of common shares and equivalents:
Basic		95,969,321				86,832,590				90,957,313				85,183,306
Diluted		95,969,321				86,832,590				90,957,313				85,183,306

STEREOTAXIS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share amounts)	December 31, 2025				December 31, 2024
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	13,421			$	12,217
Restricted cash - current		-				219
Accounts receivable, net of allowance of $541 and $582 at 2025 and 2024, respectively		5,847				3,824
Insurance receivable		4,316				-
Inventories, net		9,567				8,331
Prepaid expenses and other current assets		698				1,848
Total current assets		33,849				26,439
Property and equipment, net		3,019				3,573
Goodwill		3,764				3,764
Intangible assets, net		6,429				7,358
Operating lease right-of-use assets		4,912				5,483
Prepaid and other non-current assets		278				107
Total assets	$	52,251			$	46,724
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	4,768			$	5,668
Accrued liabilities		2,065				2,922
Accrued legal liabilities		4,316				-
Deferred revenue		5,675				6,804
Current contingent consideration		4,894				5,638
Current portion of operating lease liabilities		642				570
Total current liabilities		22,360				21,602
Long-term deferred revenue		555				2,064
Long-term contingent consideration		4,724				6,126
Operating lease liabilities		4,794				5,436
Other liabilities		1,097				64
Total liabilities		33,530				35,292
Series A - Convertible preferred stock:
Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized, 21,008 and 21,458 shares outstanding at 2025 and 2024, respectively		5,240				5,352
Stockholders' equity:
Common stock, par value $0.001; 300,000,000 shares authorized, 95,339,628 and 85,326,557 shares issued at 2025 and 2024, respectively		95				85
Additional paid-in capital		596,960				567,926
Treasury stock, 4,015 shares at 2025 and 2024		(206	)			(206	)
Accumulated deficit		(583,368	)			(561,725	)
Total stockholders' equity		13,481				6,080
Total liabilities and stockholders' equity	$	52,251			$	46,724

FAQ

What were Stereotaxis (STXS) full-year 2025 revenue and growth rates?

Stereotaxis reported $32.4 million in revenue for 2025, a 20% increase year-over-year. According to the company, recurring revenue rose to $22.2 million and system revenue reached $10.2 million, reflecting product launches and partial system recognitions.

How did Stereotaxis (STXS) perform in Q4 2025 and what drove the increase?

Q4 2025 revenue was $8.6 million, up 36% year-over-year driven by system and recurring sales. According to the company, system revenue included partial recognition on two Genesis robots and recurring revenue benefitted from MAGiC Sweep and MAGiC contributions.

What is Stereotaxis (STXS) guidance and outlook for 2026 revenue?

Stereotaxis expects double-digit revenue growth and annual revenue to surpass $40 million in 2026. According to the company, growth depends on manufacturing ramps for GenesisX and MAGiC and achieving four commercial and regulatory milestones outlined for the year.

What is Stereotaxis (STXS) cash position and liquidity at year-end 2025?

At December 31, 2025, Stereotaxis held $13.4 million in cash and had no debt on its balance sheet. According to the company, it also raised $3.1 million in Q4 via an at-the-market offering to support commercialization and working capital needs.

What are the key near-term commercial milestones Stereotaxis (STXS) plans in 2026?

Stereotaxis aims to establish five GenesisX programs, ramp MAGiC to 500 catheters/month, show endovascular robotics strategy, and gain FDA approval for Synchrony. According to the company, these milestones target manufacturing scale-up, commercial adoption, and initial AI features for the digital suite.